Results 41 to 50 of about 69,773 (297)

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Metastases risk in thin cutaneous melanoma: Prognostic value of clinical-pathologic characteristics and mutation profile [PDF]

, 2018
Background: A high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases.
Calvieri, Stefano, Carbone, Anna, Donati, Pietro, Frascione, Pasquale, MARRAFFA, FEDERICA, Mattia, Cinzia Di, Ottini, Laura, Paolino, Giovanni, Richetta, Antonio G., Rizzolo, Piera, Silvestri, Valentina, Valentini, Virginia, Zelli, Veronica   +12 more
core   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, EarlyView.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

RAS oncogenes direct metastasis

Molecular & Cellular Oncology, 2017
RAS genes are cardinal driver oncogenes frequently and differentially mutated across bodily tumors. Their tumorigenic potential has been mainly ascribed to autonomous promotion of tumor cell proliferation and survival. However, recent evidence shows that
Magda Spella, Antonia Marazioti, Kristina A. M. Arendt, Georgios T. Stathopoulos   +3 more
doaj   +1 more source

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2019
Inhibition of the RAS-RAF-ERK-pathway using sorafenib as a first-line and regorafenib as a second-line treatment approach is the only effective therapeutic strategy for advanced hepatocellular carcinoma (HCC).
Peter Dietrich, Anne Gaza, Laura Wormser, Valerie Fritz, Claus Hellerbrand, Anja Katrin Bosserhoff   +5 more
doaj   +1 more source

Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou, Marc Jaskir, Julian Gal, Yombe Fonkeu, Christos Davatzikos, MacLean P. Nasrallah, Jose Garcia, Stephen J. Bagley, Arati Desai, Richard E. Phillips, Steven Tobochnik, Colin A. Ellis, James J. Gugger, Nishant Sinha, Joel M. Stein, Kathryn A. Davis   +15 more
wiley   +1 more source

Cutis Verticis Gyrata Differential Diagnosis: Clinical Case

Вопросы современной педиатрии
Background. Cutis verticis gyrata is rare benign scalp disorder characterized by excessive skin and subcutaneous tissue proliferation and hypertrophy. Nowadays, there are three forms of this disease with various developmental mechanisms and associated ...
Tatiana S. Belysheva, Ekaterina E. Zelenova, Tatiana A. Gassan, Eduard T. Ambarchyan, Malika I. Denieva, Yana V. Vishnevskaya, Tatiana V. Nasedkina, Nikolay N. Murashkin   +7 more
doaj   +1 more source

Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness

Breast Cancer Research, 2022
Background Ductal carcinoma in situ (DCIS) is the most common type of in situ premalignant breast cancers. What drives DCIS to invasive breast cancer is unclear. Basal-like invasive breast cancers are aggressive.
Ze-Yi Zheng, Hanan Elsarraj, Jonathan T. Lei, Yan Hong, Meenakshi Anurag, Long Feng, Hilda Kennedy, Yichao Shen, Flora Lo, Zifan Zhao, Bing Zhang, Xiang H.-F. Zhang, Ossama W. Tawfik, Fariba Behbod, Eric C. Chang   +14 more
doaj   +1 more source

Identification of NRAS Downstream Genes with CRISPR Activation Screening

Biology, 2022
Mutations in NRAS constitutively activate cell proliferation signaling in malignant neoplasms, such as leukemia and melanoma, and the clarification of comprehensive downstream genes of NRAS might lead to the control of cell-proliferative signals of NRAS ...
Akiya Tatsumi, Haruka Hirakochi, Satomi Inoue, Yosuke Tanaka, Hidehiro Furuno, Masumi Ikeda, Sachiko Ishibashi, Towako Taguchi, Kouhei Yamamoto, Iichiroh Onishi, Zohar Sachs, David A. Largaespada, Masanobu Kitagawa, Morito Kurata   +13 more
doaj   +1 more source

Inhibition and degradation of NRAS with a pan-NRAS monobody

Oncogene
AbstractThe RAS family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three RAS isoforms (HRAS, KRAS, or NRAS) are found in nearly 20% of all human tumors with NRAS mutated in ~25% of melanomas.
Michael Whaby, Gayatri Ketavarapu, Akiko Koide, Megan Mazzei, Mubashir Mintoo, Eliezra Glasser, Unnatiben Patel, Cecile Nasarre, Matthew J. Sale, Frank McCormick, Shohei Koide, John P. O’Bryan   +11 more
openaire   +4 more sources